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Abstract
Objective: Calcitriol and 1-α-hydroxy vitamin D3 can be regarded as equivalent compounds in terms
of their biochemical activity, because the latter can be rapidly converted to the former in the liver.
This study aimed to examine whether calcitriol and 1-α-hydroxy vitamin D3 could be used
interchangeably on a weight-to-weight basis in treating secondary hyperparathyroidism.
Methods: We enrolled 24 (11 men and 13 women) peritoneal dialysis patients with serum intact
parathyroid hormone levels greater than 10 pmol/L, who were stable on calcitriol. The mean age
was 51.9 ± 12.5 years. Patients were observed for 8 weeks, and then calcitriol was changed to 1-
α-hydroxy vitamin D3 on a weight-to-weight basis. Patients were followed-up for a further 16 weeks.
Twenty patients had intermittent pulse therapy; four had regular daily therapy. The average dosage
of calcitriol before conversion was 0.3 ± 0.11 µg/d, or 1 µg twice weekly. The duration of dialysis
was 23.5 ± 16.7 months.
Results: Serum calcium, phosphate, and alkaline phosphatase levels remained stable after
conversion. Median serum intact parathyroid hormone levels before and after conversion were 54.6
and 49.4 pmol/L, respectively (p=0.414 by Friedman’s test). Two patients had mild asymptomatic
hypercalcemia after conversion. Serum calcium level returned to normal within a few days after
the dosage of calcium supplement and 1-α-hydroxy vitamin D3 has been reduced.
Conclusions: We conclude that calcitriol and 1-α-hydroxy vitamin D3 have equivalent efficacy in
treating secondary hyperparathyroidism.
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INTRODUCTION
Renal osteodystrophy is a major problem in patients with
end-stage renal disease (ESRD) (1). The pathogenesis
of secondary hyperparathyroidism associated with ESRD
is complicated. Relative or absolute deficiency of
calcitriol is one of the major contributing factors of
excessive parathyroid hormone (PTH) secretion (2).
Calcitriol also acts directly on the parathyroid glands
through specific vitamin D receptors to suppress the
transcription of messenger RNA for prepro-PTH (3,4).
Thus, calcitriol and 1-α-hydroxy-vitamin-D3 (1α[OH]
D3) have been used extensively to treat dialysis patients
with secondary hyperparathyroidism.
Early study in patients with chronic kidney failure
suggested that calcitriol was twice as potent as 1α(OH)
D3 (5). However, under normal physiological
circumstances, 1α(OH)D3 is quickly and completely
hydroxylated to calcitriol in the liver. As a result, 1α
(OH)D3 and calcitriol could be regarded, at least
theoretically, as equivalent compounds. Successful
treatment of secondary hyperparathyroidism in dialysis
patients by regular and pulse oral 1α(OH)D3 and
calcitriol has been reported (6-9). The assumption that
these two compounds are clinically equivalent has not
been extensively evaluated. In this study, we examined
the effect of conversion from calcitriol to 1α(OH)D3 on
a weight-to-weight basis.
METHODS
We enrolled 24 stable peritoneal dialysis patients in the
Prince of Wales Hospital, Hong Kong. Inclusion criteria
were 1. moderate to severe hyperparathyroidism, defined
as a serum intact PTH (iPTH) level greater than 10
pmol/L; 2. treatment for at least 4 months with oral
calcitriol, either regular or pulse therapy, at static dosage;
and 3. stable plasma biochemistry for at least 3 months.
Criteria for exclusion included 1. any underlying medical
condition (eg, malabsorption syndrome or severe liver
disease) that might alter the absorption or metabolism
of 1α(OH)D3; 2. any condition that might have precluded
a patient from remaining in the study (eg, alcohol or drug
abuse, malignancy, or psychiatric disorder); and 3. plans
for parathyroid surgery within 4 months.
Informed consent was obtained. Patients were observed
for 8 weeks and were maintained on calcitriol therapy.
At week 8, calcitriol was changed to 1α(OH)D3 (One-
Alpha, Leo Pharmaceutical Products, Copenhagen,
Denmark) on a weight-to-weight basis. To avoid rebound
hyperparathyroidism, a washout period was not used. The
dosage of calcium supplement and phosphate binder was
not altered.
Clinical conditions of all patients were observed at the
beginning of study, and at weeks 4, 8, 10, 12, 16, 20,
and 24 of the study. Compliance was checked by pill
count. Renal function test, plasma calcium, phosphate,
albumin, and alkaline phosphatase levels were checked
during every visit. Serum iPTH level was measured at
weeks 0, 8, 12, 16, and 24 and was assayed by a solid-
phase, two-site chemiluminescent immunometric assay
(Diagnostic Products Corporation, California, US). The
average iPTH levels at the beginning of study and at
week 8 were taken as preconversion levels; the mean
iPTH levels at weeks 12 and 16 were taken as
postconversion levels. When plasma calcium level fell
below 2 mmol/L, the dosage of 1α(OH)D3 was increased
according to clinical response. When plasma calcium
levels rose above 2.8 mmol/L, the dosage of calcium
supplement was reduced until the calcium level fell below
2.5 mmol/L. The dosage of 1α(OH)D3 was reduced if
the serum calcium level failed to normalize.
All data were described as mean values ± standard
deviation unless otherwise specified. Statistical analysis
was performed by using analysis of variance for repeated
measures. Because the results of serum iPTH levels were
significantly skewed, the data were compared by
Friedman’s test for serial measures. A p value of less
than 0.05 was considered significant.
RESULTS
We enrolled 24 patients; 11 (45.8%) were men and 13
(54.2%) were women. The mean age was 51.9 ± 12.5
years. Mean duration of dialysis before enrollment was
23.5 ± 16.7 months (range, 4-66 months). The underlying
renal diagnoses were diabetic nephropathy (10 cases),
chronic glomerulonephritis (eight), polycystic kidney
(two), and unknown (four). Two (8.3%) patients were
carriers of hepatitis B surface antigen, but none had any
clinical or laboratory evidence of chronic liver disease.
Common clinical manifestations of secondary hyper-
parathyroidism were vascular calcification (10 cases),
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radiologic abnormalities (six) such as osteopenia, bone
cysts, or osteosclerosis, bone pain (two), and valvular
calcification (one). Fourteen (58.3%) patients had
moderately raised serum iPTH levels without clinical
signs and symptoms. The baseline iPTH level was 55.7
± 39.2 pmol/L. None of the 24 patients had evidence of
nodular parathyroid enlargement by ultrasonography or
radioisotope scan. The patients had been taking calcitriol
for 23.5 ± 16.7 months before enrollment into the study.
Twenty (83.3%) patients had intermittent pulse calcitriol
therapy, with median dosage of 1 µg twice weekly; four
(16.6%) patients had regular daily calcitriol therapy, with
a mean dosage of 0.3 ± 0.11 µg/d. All except one of the
patients used calcium carbonate as a phosphate binder;
the mean dosage before conversion was 4.9 ± 2.8 g/d in
divided doses.
The biochemical profile and serum iPTH levels before
and after conversion to 1α(OH)D3 are summarized in
Figures 1 and 2, respectively. Median serum iPTH levels
before and after conversion to 1α(OH)D3 were 54.6 and
49.4 pmol/L, respectively (p=0.414 by Friedman’s test).
Serum phosphate levels began to rise 8 weeks after
conversion to 1α(OH)D3, from 1.54 ± 0.46 to 1.74 ±
0.63 mmol/L. The increase, however, was not statistically
significant (p=0.265 by repeated-measure analysis of
variance). Serum calcium and alkaline phosphates levels
remained stable throughout the study period.
None of the patients needed an increase in the dosage of
phosphate binder after conversion to 1α(OH)D3. Two
patients had mild hypercalcemia after conversion, with
peak calcium levels of 2.9 and 3 mmol/L. Both patients
Figure 1. Biochemical profiles during the study period. (A) Serum calcium level; (B)
serum phosphate level; (C) serum alkaline phosphates level. Error bars denote
standard errors of mean.
ALP = alkaline phosphates
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were asymptomatic and required reduction in the dosage
of oral calcium supplement. In one patient, serum calcium
level normalized only after reduction in the dosage of
1α(OH)D3. There was no other significant adverse effect
reported for either vitamin D supplement.
DISCUSSION
The production of 1,25(OH)2D3 by the kidney has a
pivotal physiological role in maintaining serum calcium
levels by modulating active intestinal calcium absorption,
facilitating the release of calcium from bone, and en-
hancing renal tubular calcium reabsorption. Serum 1,25
(OH)2D3 levels decline progressively as renal function
deteriorates. This change accounts at least partially for
the impaired intestinal calcium absorption and moderate
decreases in serum calcium concentrations in patients
with moderate to advanced kidney failure. In patients
with ESRD, active vitamin D analog is an effective
treatment of renal osteodystrophy.
Although 1α(OH)D3 is rapidly and completely converted
to calcitriol in the liver, and the two compounds could
be considered chemically equivalent, one study in pa-
tients with chronic renal failure suggested that calcitriol
was twice as potent as 1α(OH)D3 (5). Nevertheless, some
investigators still believe that the action of 1α(OH)D3
and calcitriol are similar. In this study, we examined
whether calcitriol and 1α(OH)D3 could be used
interchangeably on a weight-to-weight basis, for the
treatment of secondary hyperparathyroidism compli-
cating ESRD.
We found that 1α(OH)D3 could be used in place of
calcitriol in most patients without alteration of dosage.
We therefore conclude that calcitriol and 1α(OH)D3 had
equivalent efficacy in the treatment of secondary
hyperparathyroidism in patients with ESRD.
There was no washout period between the conversion of
calcitriol to 1α(OH)D3 in this study, because it would
not be ethical to withhold vitamin D therapy in pa-
tients with significant secondary hyperparathyroidism.
Furthermore, it is often difficult to achieve satisfactory
control of serum calcium and PTH levels after vitamin
D therapy has been stopped for a period of time (10).
This study focused on the short-term biochemical effects.
A longer period of observation is important in studying
the long-term effects of conversion to 1α(OH)D3,
because the increase in PTH level and secondary hyper-
parathyroidism may take some time to manifest.
The population in this study was heterogeneous by
design. We enrolled patients with variable severity of
secondary hyperparathyroidism (iPTH level, 10.1-128.5
pmol/L) who were taking either intermittent pulse oral
or regular daily calcitriol therapy. Further study on
different cohorts according to the different levels of PTH
Figure 2. Serum parathyroid hormone levels in patients before and after conversion
to 1α(OH)D3.
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level would help us understand the effects of conversion
to 1α(OH)D3 among different populations. In this study,
a trend was observed that patients with higher PTH levels
responded differently to those with lower levels of PTH
(Fig. 2). However, the number of observations was too
small for further meaningful subgroup analysis.
Calcitriol and 1α(OH)D3 were largely equivalent in most
cases of this study. Because the pharmacological half-
life of calcitriol is less than 2 days (11), it was unlikely
that the control of hyperparathyroidism after conversion
to 1α(OH)D3 was a delayed effect of calcitriol. We did
not examined the effects of conversion from 1α(OH)D3
back to calcitriol, because 1α(OH)D3 has a longer half-
life (11) and a washout period is not desirable for patients
in this study. The nature of this study also limited the
comparison of the long-term efficacy of the two agents.
We observed a gradual increase in serum phosphate levels
after conversion to 1α(OH)D3 (Fig. 1), which may be
caused by an increase in dietary phosphate intake, or an
increase in phosphate absorption because of better
compliance to the medication. An increase in hyper-
parathyroid bone activities is less likely, possibility
because serum PTH levels remained stable (Fig. 2).
Both agents were well tolerated, and 1α(OH)D3 was also
effective in chronic hepatitis B carriers (data not shown).
There were case reports of using 1α(OH)D3 in cirrhotic
patients (12). Although prolonged hypercalcemia was a
theoretical risk of 1α(OH)D3 (8,13), this problem was
not observed in this study. Both patients in whom
hypercalcemia developed after conversion to 1α(OH)D3
responded in a few days to the reduction of calcium
supplementation and 1α(OH)D3.
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